| Literature DB >> 11970991 |
Janice M Kelly1, Kazuyoshi Takeda, Phillip K Darcy, Hideo Yagita, Mark J Smyth.
Abstract
We have investigated the primary and secondary immunity generated in vivo by a MHC class I-deficient tumor cell line that expressed CD80 (B7-1). CD80 expression enhanced primary NK cell-mediated tumor rejection in vivo and T cell immunity against secondary tumor challenge. CD80 expression enhanced primary NK cell-mediated tumor rejection, and both NK cell perforin and IFN-gamma activity were critical for the rejection of MHC class I-deficient RMA-S-CD80 tumor cells. This primary rejection process stimulated the subsequent development of specific CTL and Th1 responses against Ags expressed by the MHC class I-deficient RMA-S tumor cells. The development of effective secondary T cell immunity could be elicited by irradiated RMA-S-CD80 tumor cells and was dependent upon NK cells and IFN-gamma in the priming response. Our findings demonstrate a key role for IFN-gamma in innate and adaptive immunity triggered by CD80 expression on tumor cells.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11970991 DOI: 10.4049/jimmunol.168.9.4472
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422